PacBio Brings AI And Data Science Experience To Its Board With Christopher Gibson Appointment

PacBio, a company known for its high-quality long-read sequencing technologies, announced that Christopher Gibson, Ph.D., has been appointed to its Board of Directors. The appointment brings additional experience in artificial intelligence, data science, and biotechnology to the company’s leadership as it continues to advance sequencing technologies and data-driven biological research.

Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion, a clinical-stage biotechnology company recognized for building one of the industry’s most advanced artificial intelligence-driven drug discovery platforms. During his time leading Recursion, he helped shape the company’s approach to integrating large-scale biological data with machine learning tools in order to improve and accelerate the drug discovery process.

Under Dr. Gibson’s leadership, Recursion developed a vertically integrated technology platform that combines automation, high-dimensional biological data generation, and artificial intelligence. This platform enabled the company to industrialize elements of drug discovery by creating systems capable of generating and analyzing large volumes of biological information. He guided Recursion from its early stages through significant capital raising efforts, the establishment of strategic partnerships, and its eventual public listing, helping position the company as a leader at the intersection of computational science and biology.

Christian Henry, Chief Executive Officer of PacBio, said Dr. Gibson’s experience in combining artificial intelligence, automation, and biological data has demonstrated how advanced technologies can transform scientific discovery. He noted that as PacBio continues to expand the scale of its HiFi sequencing datasets, the ability to analyze and interpret complex genomic information is becoming increasingly important. According to Henry, Dr. Gibson’s background in building and scaling an AI-focused life sciences company will help support PacBio’s long-term vision of bringing together sequencing technologies, computational tools, and data-driven research.

While at Recursion, Dr. Gibson oversaw the development of a proprietary data platform designed to generate and analyze large multimodal datasets across different stages of biomedical research. These datasets included information from drug discovery experiments, translational research, clinical studies, and electronic health records. The data platform enabled the training of machine learning models capable of identifying complex biological patterns and relationships, with the goal of accelerating clinical development and improving patient selection for new therapies.

Dr. Gibson also helped build an organization centered around expertise in computational biology, software engineering, automation systems, and scalable infrastructure. This approach supported Recursion’s efforts to apply advanced computational tools to biological research and contributed to the company’s position as a leader in AI-enabled therapeutic development.

Commenting on his new role, Dr. Gibson said he is honored to join PacBio’s Board of Directors. He noted that biological systems are extremely complex and that progress in diagnosing and treating disease depends on improving the ability to understand and decode that complexity. He also emphasized the importance of high-quality biological data in enabling meaningful scientific breakthroughs.

Dr. Gibson added that PacBio’s long-read sequencing technologies generate some of the most detailed biological datasets in the industry. According to him, combining advanced sequencing with algorithmic and artificial intelligence-based analysis will play an important role in shaping the future of healthcare. He believes the integration of sequencing technologies and AI-driven analytics offers a major opportunity to accelerate scientific discovery, improve diagnostics, and support the development of new treatments. 

Through his role on the board, Dr. Gibson will work with PacBio’s leadership team and fellow board members to help guide the company as it continues to expand its sequencing capabilities and strengthen the connection between genomic data, advanced analytics, and biomedical innovation.